Excision BioTherapeutics scores $10 mln seed
Excision BioTherapeutics, a developer of advanced gene editing therapeutics that treat life-threatening disease caused by neurotropic viruses, has closed $10 million in seed funding. ARTIS Ventures led the round.
6 September 2017•1 min read
